All News EirGenix Inc.

Equities

6589

TW0006589005

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-06-04 EDT			5-day change	1st Jan Change
80 ^TWD	+0.88%		0.00%	-20.40%

05-15	EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-22	EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	03-08	CI
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC	11-22	CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei	11-09	CI
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar	23-09-18	MT
Novartis Cancer Drug Gets Marketing Recommendation from European Medicines Agency	23-09-18	DJ
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar	23-09-18	MT
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System	23-09-18	CI
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe	23-05-02	CI
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
EirGenix Inc. announced a financing transaction	23-03-09	CI
EirGenix Inc. Announces Executive Changes	23-01-10	CI
Eirgenix Inc. Announces Establishment of Corporate Governance Committee	22-12-28	CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Eirgenix, Inc., Submits the Biosimilar Drug Eirgasum of 150 Mg Powder for Concentratefor Solution for Infusion Presentation New Drug Application to the Taiwan Food and Drug Administration	22-09-30	CI
EirGenix Inc. Appoints Po-Chih Chen as Remuneration Committee	22-09-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News EirGenix Inc.

Equities

6589

TW0006589005

All News

Filters